Is the Moderna vaccine effective against the Omicron Variant?
Speaking on mRNA-1273 and its effectiveness in trials against Omicron, Dr Paul Burton said: “It’s highly effective, and it’s extremely safe.
avatar
Precious Njoku is a Financial Writer with extensive knowledge about the stock market.
2021-12-21 17:56

The coronavirus disease (COVID-19) is caused by the SARS-COV-2 virus. Since its discovery in December 2019, it has continued to spread widely and cause several deaths and hospitalizations. The virus has the uncanny ability to produce variants. A virus variant is a mutation or change in the virus and evolution that causes it to spread among people. There have been several recent variants, including the dominant Delta variant and recently the Omicron variant. The Delta variant is relatively presently under control, but the latest variant, the Omicron variant, has been labelled “a variant of concern” by the World Health Organization (WHO).

Is the Moderna vaccine effective against the Omicron Variant?
Health bodies worldwide know very little about the Omicron variant since its discovery one month ago in a South African lab. But according to recent reports from the WHO, the Omicron variant is rapidly spreading and appears to be doubling in 1.5 to 3 days in areas that have community transmission. The world reacted in fear of this new variant as several countries closed their borders to South Africa. Yet, this variant has continued to spread around the globe and is now in 89 countries.

Moderna (NASDAQ: MRNA) is one of the companies which has reported that its vaccine is effective against the Omicron variant. Last year the FDA approved taking two shots of the Moderna vaccine named mRNA-1273, both of 100 micrograms. Then later, due to the spread of variants like the Delta variant, booster shoots of 50 micrograms were also approved. Recently, the company reported that booster shots of the 1273 vaccine appeared effective against the Omicron variant after laboratory tests.

According to Moderna’s chief medical officer, Dr Paul Burton, mRNA-1273 would be the company’s “first line of defence against Omicron.” He further stated that Moderna plans to develop another vaccine specifically against Omicron. However, the decision to focus on the existing vaccine is because the Omicron variant is fast spreading, and little is known about it.

Speaking on mRNA-1273 and its effectiveness in trials against Omicron, Dr Paul Burton said: “It’s highly effective, and it’s extremely safe. I think it will protect people through the coming holiday period and through these winter months when we’re going to see the most severe pressure of Omicron.”

During the lab tests of the vaccine against the Omicron variant, the company reported that the two-dose regimen produces low antibodies that neutralize against Omicron, but there were a 37 times boost on neutralizing antibodies when the 50 microgram booster shot was taken. Meanwhile, it was also discovered that if the booster shot was at 100 micrograms, there was an 80-times increase in neutralizing antibodies. However, the data were from lab tests conducted in Moderna’s labs and were not peer-reviewed.

Meanwhile, the UK health authorities reported that based on their research on the Omicron variant, taking booster shots of the current vaccines has proved to be 80% effective against the Omicron variant. This is encouraging news as the world is still reeling from the emotional, economic, and traumatic effects of the Covid-19 disease and its many variants.


Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

positive
negative
Published On
2021-12-21 17:56

avatar
About the Author
Precious Njoku is a Financial Writer with extensive knowledge about the stock market.


buy-coffee
You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

Is Rivian (RIVN) Stock a Buy Again?
The company continues to bleed money and is losing more than $40,000 per vehicle.
By Mike Sakuraba | 2 weeks ago

2 Stocks to Buy on a Pullback
Here are two stocks I’ll buy if we pull back in March.
By Mike Sakuraba | 2 weeks ago

2 Stocks to Buy for the March Bull Run
Here are 2 I have my eyes on for March.
By Mike Sakuraba | 3 weeks ago

Bitcoin is Hot: 2 Stocks to Buy Now
Here are 2 lesser-known crypto stocks that I think will benefit from Bitcoin’s bull run.
By Mike Sakuraba | 3 weeks ago

2 Stocks to Buy on the Earnings Dip
Here are two stocks that sold off that I have my eye on!
By Mike Sakuraba | 3 weeks ago

2 Stocks I'm Never Buying Again
Never is such a strong word but when it comes to investing, it is easy to never want to buy a stock again.
By Mike Sakuraba | 1 month ago

2 Stocks to Ride the NVIDIA Hype Train
Now that NVIDIA (NASDAQ: NVDA) saved the market again, is it finally time to buy?
By Mike Sakuraba | 1 month ago

Is it Too Late to Buy SMCI Stock?
Is it too late to get into SMCI after this parabolic run?
By Mike Sakuraba | 1 month ago